Risk of recurrence of unusual site venous thromboembolism

Hamostaseologie

Volumn 33, Issue 3, 2013, Pages 225-231

  Riva, N ^a   Dentali, F ^a   Donadini, M P ^a   Squizzato, A ^a   Ageno, W ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Cerebral vein thrombosis; Recurrence; Retinal vein occlusion; Splanchnic vein thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN VEIN; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MYELOPROLIFERATIVE NEOPLASM; PATHOGENESIS; RECURRENCE RISK; RECURRENT DISEASE; RETINA VEIN OCCLUSION; RISK FACTOR; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84881510985     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-03-0006     Document Type: Article

References (71)

1. Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-1716.
2. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
3. Kearon C, Akl EA, Comerota AJ et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e419S-e494S.
4. Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
5. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121: 1630-1636.
6. Tosetto A, Iorio A, Marcucci M et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-1025.
7. Dentali F, Ageno W. Cerebral vein thrombosis. Intern Emerg Med 2010; 5: 27-32.
8. Dentali F, Squizzato A, Marchesi C et al. D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10: 582-589.
9. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-1798.
10. Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost 2010; 103: 1136-1144.
11. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006; 107: 2766-2773.
12. Passamonti SM, Biguzzi E, Cazzola M et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 2012; 10: 998-1003.
13. Bellucci S, Cassinat B, Bonnin N et al. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99: 1119-1120.
14. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood 2006; 108: 1129-1134.
15. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-e449.
16. Einhäupl K, Stam J, Bousser MG et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229-1235.
17. Ageno W, Dentali F, Squizzato A et al. Evidence and clinical judgment: Treatment of cerebral vein thrombosis. Thromb Haemost 2010; 103: 1109-1115.
18. Preter M, Tzourio C, Ameri A, Bousser MG. Longterm prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996; 27: 243-246.
19. Ferro JM, Canhão P, Stam J et al. ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670.
20. Gosk-Bierska I, Wysokinski W, Brown RD Jr et al. Cerebral venous sinus thrombosis: Incidence of venous thrombosis recurrence and survival. Neurology 2006; 67: 814-819.
21. Martinelli I, Bucciarelli P, Passamonti SM et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121: 2740-2746.
22. Dentali F, Poli D, Scoditti U et al. CErebral Vein Thrombosis International Study Investigators. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10: 1297-1302.
23. Hayreh SS: Occlusion of the central retinal vessels. Br J Ophthalmol 1965; 49: 626-645.
24. Cheung N, Klein R, Wang JJ et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multi-ethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49: 4297-4302.
25. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429-441.
26. Rogers S, McIntosh RL, Cheung N et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-319.
27. The Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol 1993; 111: 1087-1095.
28. Yau JW, Lee P, Wong TY et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38: 904-910.
29. Marcucci R, Sofi F, Grifoni E et al. Retinal vein occlusions: a review for the internist. Intern Emerg Med 2011; 6: 307-314.
30. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
31. Cole MD, Dodson PM, Hendeles S. Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension. Br J Ophthalmol 1989; 73: 693-698.
32. Dodson PM, Kritzinger EE, Clough CG. Diabetes mellitus and retinal vein occlusion in patients of Asian, West Indian and White European origin. Eye (Lond) 1992; 6: 66-68.
33. Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-554.
34. Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993; 116: 286-296.
35. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
36. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-141.
37. McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978; 138: 216-220.
38. Janssen MC, den Heijer M, Cruysberg JR et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A metaanalysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
39. Glacet-Bernard A, Coscas G, Chabanel A et al. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996; 103: 551-560.
40. Rehak J, Dusek L, Chrapek O et al. Initial visual acuity is an important prognostic factor in patients with branch retinal vein occlusion. Ophthalmic Res 2011; 45: 204-209.
41. Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: OP166-OP177.
42. Rogers SL, McIntosh RL, Lim L et al. Natural history of branch retinal vein occlusion: an evidencebased systematic review. Ophthalmology 2010; 117: 1094-1101.
43. McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidencebased systematic review. Ophthalmology 2010; 117: 1094-1123.
44. Sodi A, Giambene B, Marcucci R et al. Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion. Eur J Ophthalmol 2008; 18: 233-238.
45. Cugati S, Wang JJ, Knudtson MD et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114: 520-524.
46. Khan Z, Almeida DR, Rahim K et al. 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. Can J Ophthalmol 2013; 48: 40-45.
47. De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010; 5: 487-494.
48. Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology 1991; 13: 650-655.
49. Ögren M, Bergqvist D, Björck M et al. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23 796 consecutive autopsies. World J Gastroenterol 2006; 12: 2115-2119.
50. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg 2008; 95: 1245-1251.
51. Rajani R, Melin T, Björnsson E et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int 2009; 29: 253-259.
52. Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19: S204-S211.
53. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastro - enterol Hepatol 2010; 8: 200-205.
54. Ageno W, Squizzato A, Togna A et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost 2012; 10: 158-160.
55. Ikeda M, Sekimoto M, Takiguchi S et al. Total splenic vein thrombosis after laparoscopic splenectomy: a possible candidate for treatment. Am J Surg 2007; 193: 21-25.
56. Kralovics R, Passamonti F, Buser AS et al. A gainof- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
57. Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 2010; 5: 22-28.
58. Dentali F, Squizzato A, Brivio L et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-5623.
59. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost 2008; 99: 675-682.
60. Janssen HL, Meinardi JR, Vleggaar FP et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364-2368.
61. De Stefano V, Za T, Ciminello A et al. Causes of adult splanchnic vein thrombosis in the mediterranean area. Mediterr J Hematol Infect Dis 2011; 3: e2011063.
62. Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10: 1-10.
63. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol 1997; 92: 858-862.
64. Amitrano L, Guardascione MA, Scaglione M et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007; 102: 2464-2470.
65. Condat B, Pessione F, Hillaire S et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-497.
66. Amitrano L, Guardascione MA, Menchise A et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-451.
67. Delgado MG, Seijo S, Yepes I et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-783.
68. Senzolo M, M Sartori T, Rossetto V et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-927.
69. Dentali F, Ageno W, Witt D et al. WARPED consortium. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost 2009; 102: 501-504.
70. Darwish Murad S, Plessier A, Hernandez-Guerra M et al. EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175.
71. Cruz E, Ascher NL, Roberts JP et al. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant 2005; 19: 501-506.